Making Strides in Targeting PARP, ATR, ATM, WEE1 and POLθ AstraZeneca and Merck are at the forefront of DDR inhibitor development, focusing on next-generation PARP inhibitors...

Proteomics offers huge advantages for the discovery and pre-clinical development of small molecule drugs and their translation into robust clinical candidates. Just this year,...